IPX066 versus immediate-release (IR) carbidopa-levodopa (CD-LD), Phase III results
 

Positive top-line results from IPX066 [versus immediate-release (IR) carbidopa-levodopa (CD-LD)] Phase III study in patients with PD

http://neurotalk.psychcentral.com/sh...082#post753082

http://web.servicebureau.net/conf/me...te_ticker=IPXL

webcast on this drug by IPXL
http://phx.corporate-ir.net/External...xUeXBlPTI=&t=1

only compared against immediate release sinemet so i can't get that excited.

enrolling for sinemet + entacapone vs IPX066

strange they aren't comparing against sustained release.

2 hours
 

i can't get excited either. i already know what sinemet and entacapone do to me [dyskinesai] so the 2 extra hours may be spent miserably.

sorry to be such a cynic!

Subjects converted to IPX066 experienced a reduction from baseline of more than 2 hours in total "off time" during waking hours, and this effect was maintained in the group then randomized to IPX066 during the blinded study portion. While the group treated with IR CD-LD achieved similar improvement during conversion to IPX066, "off time" worsened by 1.0 hours during double blind treatment with IR CD-LD (p<0.0001). In addition, during double-blind treatment, subjects experienced similar results in "on time" without troublesome dyskinesia with an increase of 1.9 hours for IPX066 compared to an increase of 0.8 hours for IR CD-LD as measured from study entry (p<0.001).

their whole pitch is more even blood levels, fewer pills, likely reduced dyskinesias. hauser from USF was conference call participant, said he would prescribe to 30% of his patients taking sinemet who had fluctuations when asked. worth a listen. seems they are ramping up sales force and factory so i guess u.s. and european approval a certainty?

sales manager said they will be contacting neuros and the many GP's acting as neuros. made me chuckle/sad.